CRISPR Therapeutics AG
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $-52.9M | $-55.9M | $3.0M | $10.8M |
| FY2017 | $-70.1M | $-77.9M | $7.8M | $18.9M |
| FY2018 | $-96.2M | $-99.0M | $2.8M | $35.0M |
| FY2019 | $56.7M | $50.0M | $6.7M | $44.1M |
| FY2020 | $-238.4M | $-256.7M | $18.4M | $66.0M |
| FY2021 | $539.0M | $457.3M | $81.7M | $102.4M |
| FY2022 | $-495.7M | $-532.9M | $37.2M | $97.9M |
| FY2023 | $-260.4M | $-269.8M | $9.5M | $81.0M |
| FY2024 | $-142.8M | $-144.7M | $1.9M | $86.6M |
| FY2025 | $-345.0M | $-345.9M | $914.0K | $72.5M |